Winningham Rick E 4
4 · Theravance Biopharma, Inc. · Filed Nov 19, 2024
Insider Transaction Report
Form 4
Winningham Rick E
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Award
Ordinary Shares
2024-11-14$9.57/sh+3,193$30,557→ 1,827,092 total
Holdings
- 3,900(indirect: As Custodian)
Ordinary Shares
- 92,567(indirect: By Trust)
Ordinary Shares
Footnotes (1)
- [F1]This transaction is being reported late due to inadvertent administrative error. Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on November 14, 2024. Transaction was with the Issuer and did not involve an open market transaction.